Search

Your search keyword '"Quirino, T."' showing total 80 results

Search Constraints

Start Over You searched for: Author "Quirino, T." Remove constraint Author: "Quirino, T." Topic medicine.medical_specialty Remove constraint Topic: medicine.medical_specialty
80 results on '"Quirino, T."'

Search Results

1. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2. Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

3. Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy

4. First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison

5. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study

6. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

7. Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study

8. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART

9. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

10. Drop in CD4+ counts below 200 cells/µL after reaching (or starting from) values higher than 350 cells/µL in HIV‐infected patients with virological suppression

11. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance

12. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

13. Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy

14. Weight Gain: A Possible Side Effect of All Antiretrovirals

15. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

16. Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV

17. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study

18. Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy

19. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study

20. Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice

21. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort

22. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

23. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort

24. Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus

25. Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women: Data From the ICONA Foundation Study Group, Years 1997-2013

26. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study

27. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

28. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

29. Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study

30. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

31. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

32. Simit Epidemiological Multicentric Study on Hospitalized Immigrants in Italy During 2002

33. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort

34. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

35. TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality

36. Inconsistent condom use among HIV-positive women in the ‘‘Treatment as Prevention Era’’: data from the Italian DIDI study

37. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study

38. Anticonvulsant hypersensitivity syndrome due to carbamazepine

39. Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project

40. Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)

41. Effectiveness of first-generation HCV protease inhibitors: Does HIV coinfection still play a role?

42. Low frequency of skin reactions in a cohort of patients on raltegravir

43. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study

44. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

45. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

46. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals

47. High parathyroid hormone concentration in tenofovir-treated patients are due to inhibition of calcium-sensing receptor activity

48. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

49. PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection

50. HIV clinical pathway: A new approach to combine guidelines and sustainability of anti-retroviral treatment in Italy

Catalog

Books, media, physical & digital resources